{"id":16757,"date":"2026-05-22T08:01:10","date_gmt":"2026-05-22T08:01:10","guid":{"rendered":"https:\/\/www.europesays.com\/be\/16757\/"},"modified":"2026-05-22T08:01:10","modified_gmt":"2026-05-22T08:01:10","slug":"belgium-full-life-technologies-raises-us150m-to-advance-clinical-stage-assets","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/be\/16757\/","title":{"rendered":"Belgium: Full-Life Technologies raises US$150m to advance clinical stage assets"},"content":{"rendered":"<p><a href=\"https:\/\/www.linkedin.com\/company\/full-life-technologies\/\" rel=\"nofollow noopener\" target=\"_blank\">Full-Life Technologies<\/a>, a clinical stage radiotherapeutics company with operations in Belgium, Germany, and China, has raised US$150m led by Vivo Capital. Vivo was joined in the financing package, consisting of \u00a0US$109m in Series D equity and US$41m in debt, by Full-Life\u2019s strategic partner SK Biopharmaceuticals and Chengwei Capital, HSG, Junson Capital, Plaisance, Sky9 Capital, Yunion, as well as other shareholders.<\/p>\n<p>Proceeds will be used to advance the company\u2019s clinical stage assets, including [225Ac]-FL-020 for prostate cancer and [225Ac]-FL-261 for multiple solid tumour indications. By year-end 2026, Full-Life expects to have three differentiated clinical stage programmes. The financing will also facilitate the initiation of GMP-grade 225Ac manufacturing at the company\u2019s plant in Belgium.<\/p>\n<p>Full-Life completed a US$77m financing in September 2025 (US$50m Series C equity and US$27m) debt led by Junson Capital. In 2024, it raised US$63.3m (US$47.3m\u00a0in Series B equity financing and\u00a0US$16m debt) led by Prosperity7 Ventures, and in 2022, it completed a US$37m Series A led by Sequoia China.\u00a0<\/p>\n<p>Press release: <a href=\"https:\/\/www.full-life.com\/media\/press-releases\/44\" rel=\"nofollow noopener\" target=\"_blank\">Full-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities-Press Releases-From Half-Life to Full-Life.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Full-Life Technologies, a clinical stage radiotherapeutics company with operations in Belgium, Germany, and China, has raised US$150m led&hellip;\n","protected":false},"author":2,"featured_media":16758,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[7,10892,10893,10894,10895,10896,10897,10898,10899,10900],"class_list":["post-16757","post","type-post","status-publish","format-standard","has-post-thumbnail","category-belgium","tag-belgium","tag-chengwei-capital","tag-full-life-technologies","tag-hsg","tag-junson-capital","tag-plaisance","tag-sk-biopharmaceuticals","tag-sky9-capital","tag-vivo-capital","tag-yunion"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@be\/116617182248913707","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts\/16757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/comments?post=16757"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts\/16757\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/media\/16758"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/media?parent=16757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/categories?post=16757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/tags?post=16757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}